- Home
- DOMO vs SEPN Comparison
DOMO vs SEPN Comparison
Compare DOMO & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- SEPN
- Stock Information
- Founded
- DOMO 2010
- SEPN 2022
- Country
- DOMO United States
- SEPN United States
- Employees
- DOMO N/A
- SEPN N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- SEPN
- Sector
- DOMO Technology
- SEPN
- Exchange
- DOMO Nasdaq
- SEPN NYSE
- Market Cap
- DOMO 436.2M
- SEPN 453.2M
- IPO Year
- DOMO 2018
- SEPN 2024
- Fundamental
- Price
- DOMO $12.70
- SEPN $10.41
- Analyst Decision
- DOMO Hold
- SEPN Buy
- Analyst Count
- DOMO 6
- SEPN 4
- Target Price
- DOMO $10.67
- SEPN $27.00
- AVG Volume (30 Days)
- DOMO 1.1M
- SEPN 559.2K
- Earning Date
- DOMO 05-21-2025
- SEPN 08-15-2025
- Dividend Yield
- DOMO N/A
- SEPN N/A
- EPS Growth
- DOMO N/A
- SEPN N/A
- EPS
- DOMO N/A
- SEPN N/A
- Revenue
- DOMO $317,052,000.00
- SEPN $977,000.00
- Revenue This Year
- DOMO $1.71
- SEPN N/A
- Revenue Next Year
- DOMO $2.43
- SEPN $526.96
- P/E Ratio
- DOMO N/A
- SEPN N/A
- Revenue Growth
- DOMO N/A
- SEPN 108.76
- 52 Week Low
- DOMO $6.01
- SEPN $4.17
- 52 Week High
- DOMO $14.83
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- DOMO 56.01
- SEPN N/A
- Support Level
- DOMO $12.86
- SEPN N/A
- Resistance Level
- DOMO $13.75
- SEPN N/A
- Average True Range (ATR)
- DOMO 0.70
- SEPN 0.00
- MACD
- DOMO -0.28
- SEPN 0.00
- Stochastic Oscillator
- DOMO 7.39
- SEPN 0.00
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.